
ICON (ICLR) Stock Forecast & Price Target
ICON (ICLR) Analyst Ratings
Bulls say
Icon is a well-established global company with a strong financial outlook and a focus on social responsibility. Despite a decline in direct-fee book-to-bill, management remains optimistic about future growth and has adjusted their outlook to include revenue growth and improved margins. The company is expected to see significant acceleration in growth in 2027, but potential risks such as government regulations and changes in the biopharma industry should be monitored.
Bears say
Icon is facing several challenges in their business, including potential lower margin rates leading to a decline in EBITDA dollar growth. Additionally, their visibility into passthrough revenues is limited, making it difficult to predict future performance. There are also risks related to further accounting reviews or restatements, failure to deliver trials on time, and securing sensitive clinical trial data. Despite being one of the largest CROs with strong relationships with top pharmaceutical companies, Icon's future financial performance is uncertain, leading to a negative outlook on their stock.
This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.
ICON (ICLR) Analyst Forecast & Price Prediction
Start investing in ICON (ICLR)
Order type
Buy in
Order amount
Est. shares
0 shares